Key result
Quinapril offers a favorable safety profile versus other ACE inhibitors but lacks recent large trials.
Why the study?
Quinapril hydrochloride is a less commonly used and less-studied ACE inhibitor approved for hypertension with off-label use in congestive heart failure and diabetic nephropathy.
What is the clinical efficacy and safety profile of quinapril compared to other ACE inhibitors?
What is the clinical efficacy and safety profile of quinapril compared to other ACE inhibitors?
Quinapril remains a safe and effective ACE inhibitor option, particularly for elderly patients or those intolerant to other ACE inhibitors, despite limited recent trial data.
Answers are grounded in this paper and cite their sources.
May support quinapril in select ACEI-intolerant patients; leaves open need for contemporary RCTs.
INTRODUCTION: Angiotensin-converting enzyme (ACE) inhibitors are a mainstay of antihypertensive therapy. Quinapril hydrochloride, a less commonly used, and less-studied ACE inhibitor has been approved for its primary use in hypertension. Studies also indicate its off-label use for congestive heart failure and diabetic nephropathy. The ANDI and TREND trials have been pivotal in demonstrating the effectiveness of quinapril. AREAS COVERED: The authors conducted a review of the literature analyzing the clinical efficacy and safety profile of quinapril. This review discusses the development of quinapril, provides an updated summary of the indications and contraindications, and presents a comparison with other ACE inhibitors. EXPERT OPINION: Quinapril is a safe and well-tolerated antihypertensive medication with a favorable safety profile compared to other ACE inhibitors. However, a lack of ample recent clinical trials and post-marketing data investigating the efficacy of quinapril in large cohorts has resulted in limited use in clinical practice. Quinapril may be an effective antihypertensive option for elderly populations as well as those who cannot tolerate the side effects profiles of other ACE inhibitors and as an additional treatment option for patients with heart failure with preserved ejection fraction.
No takes yet. Share an insight, caveat, or question.
Barkhordarian et al. (2023) conducted a review in Hypertension. Quinapril hydrochloride vs. Other ACE inhibitors was evaluated. Quinapril is a safe and well-tolerated antihypertensive medication with a favorable safety profile compared to other ACE inhibitors, though limited by a lack of recent large clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: